Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
AVTX Stock Summary
Top 10 Correlated ETFs
AVTX
In the News
Will Avalo Therapeutics, Inc. (AVTX) Report Negative Q4 Earnings? What You Should Know
Avalo Therapeutics (AVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Buy Stocks for January 3rd
GWRS, SRPT, AVTX, NTGR and PAY have been added to the Zacks Rank #1 (Strong Buy) List on January 3, 2024.
New Strong Buy Stocks for December 14th
MUSA, AVTX, ANIK, CARG and WES have been added to the Zacks Rank #1 (Strong Buy) List on December 14, 2023.
New Strong Buy Stocks for November 27th
VVI, AVTX, RYI, TM and HIBB have been added to the Zacks Rank #1 (Strong Buy) List on November 27, 2023.
New Strong Buy Stocks for November 21st
AQST, RBT, HARP, VVI and AVTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2023.
Top trending biotech stocks: ANVS, MTNB, AVTX, TPST
Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of the most notable M&A events this year were Pfizer's acquisition of Seagen, Eli Lilly's buyout of POINT Biopharma and Versanis Bio, and Roche's purchase of Good Therapeutics.
3 Hot Penny Stocks To Watch Before Next Week
Are you looking for the best penny stocks to buy after the stock market dropped today? Believe it or not there are plenty of cheap stocks to watch that are heading higher amid this big drop in major indexes.
3 Penny Stocks To Buy For Under $1, Are They Worth The Risk?
Penny stocks priced at less than one dollar seem very appealing. Just a small investment could potentially lead to huge returns.
Avalo (AVTX) Up 45% on Deal to Divest Certain Pipeline Drugs
Avalo (AVTX) will receive an upfront payment of $150,000 on selling three compounds to AUG Therapeutics. The company is also eligible to receive milestone payments of up to $45 million.
Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
WAYNE, Pa. and ROCKVILLE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.
AVTX Financial details
AVTX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 6.32 | 1.42 | 1.09 | 0.62 | 1.92 | |
Net income per share | -13.82 | -3.42 | -10.52 | -9.71 | -4.43 | |
Operating cash flow per share | -1.08 | -4.02 | -6.62 | -8.16 | -2.84 | |
Free cash flow per share | -1.27 | -4.07 | -6.63 | -8.17 | -2.85 | |
Cash per share | 3.67 | 2.36 | 3.09 | 6.28 | 1.4 | |
Book value per share | 7.22 | 4.41 | 4.01 | 2.66 | -1.16 | |
Tangible book value per share | -9.23 | 0.87 | 1.4 | 0.99 | -2.69 | |
Share holders equity per share | 7.22 | 4.41 | 4.01 | 2.66 | -1.16 | |
Interest debt per share | 5.03 | 0.03 | 0.4 | 3.56 | 2.51 | |
Market cap | 26.96B | 73.95B | 46.55B | 42.53B | 11.38B | |
Enterprise value | 26.96B | 73.94B | 46.53B | 42.5B | 11.39B | |
P/E ratio | -673.02 | -4.54K | -723.03 | -504.16 | -273.19 | |
Price to sales ratio | 1.47K | 10.96K | 6.95K | 7.88K | 630.46 | |
POCF ratio | -8.62K | -3.86K | -1.15K | -599.86 | -425.42 | |
PFCF ratio | -7.3K | -3.81K | -1.15K | -598.9 | -423.92 | |
P/B Ratio | 1.29K | 3.52K | 1.9K | 1.84K | -1.04K | |
PTB ratio | 1.29K | 3.52K | 1.9K | 1.84K | -1.04K | |
EV to sales | 1.47K | 10.95K | 6.95K | 7.87K | 630.81 | |
Enterprise value over EBITDA | 4.15K | -4.26K | -1.85K | -527.43 | -304.28 | |
EV to operating cash flow | -8.62K | -3.86K | -1.15K | -599.55 | -425.66 | |
EV to free cash flow | -7.3K | -3.81K | -1.15K | -598.6 | -424.15 | |
Earnings yield | 0 | 0 | 0 | 0 | 0 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 0.74 | 0.01 | 0.1 | 1.44 | -1.78 | |
Debt to assets | 0.22 | 0 | 0.06 | 0.42 | 0.58 | |
Net debt to EBITDA | 0.73 | 0.13 | 0.73 | 0.27 | -0.17 | |
Current ratio | 0.84 | 1.46 | 1.71 | 3.11 | 0.74 | |
Interest coverage | 48.44 | 0 | 0 | 34.35 | -8.98 | |
Income quality | 0.08 | 1.19 | 0.64 | 0.84 | 0.64 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | -0.07 | 0 | -0.39 | -0.36 | |
Sales general and administrative to revenue | 0.58 | 1.5 | 2.6 | 4.04 | 1.14 | |
Research and developement to revenue | 0.32 | 1.74 | 4.81 | 11.08 | 1.73 | |
Intangibles to total assets | 0.68 | 0.47 | 0.37 | 0.18 | 0.43 | |
Capex to operating cash flow | 0.18 | 0.01 | 0 | 0 | 0 | |
Capex to revenue | -0.03 | -0.04 | -0.01 | -0.02 | -0.01 | |
Capex to depreciation | -0.12 | -0.07 | -0.03 | -0.07 | -0.57 | |
Stock based compensation to revenue | 0.13 | 0.38 | 1.01 | 1.51 | 0.42 | |
Graham number | 47.37 | 18.4 | 30.81 | 24.1 | 10.75 | |
ROIC | -1.08 | -0.79 | -0.94 | -1.44 | -4.15 | |
Return on tangible assets | -1.77 | -0.84 | -2.32 | -1.28 | -2.2 | |
Graham Net | -10.93 | 0.01 | 0.49 | 0.12 | -3.15 | |
Working capital | -4.28M | 5.56M | 10.78M | 41.96M | -5.7M | |
Tangible asset value | -26.74M | 4.16M | 8.57M | 8.64M | -25.32M | |
Net current asset value | -27.41M | 2.61M | 6.81M | 4.71M | -27.87M | |
Invested capital | 0.74 | 0.01 | 0.1 | 1.44 | -1.78 | |
Average receivables | 6.15M | 6.93M | 4.81M | 4.59M | 3.36M | |
Average payables | 1.37M | 1.76M | 2.33M | 2.97M | 3.13M | |
Average inventory | 746.47K | 565.89K | 12K | 20.5K | 29K | |
Days sales outstanding | 171.81 | 283.51 | 238.92 | 324.5 | 38.8 | |
Days payables outstanding | 70.58 | 65.22 | 3.13K | 824.74 | 306.33 | |
Days of inventory on hand | 54.22 | 0.66 | 3.65 | 9.3 | 2.13 | |
Receivables turnover | 2.12 | 1.29 | 1.53 | 1.12 | 9.41 | |
Payables turnover | 5.17 | 5.6 | 0.12 | 0.44 | 1.19 | |
Inventory turnover | 6.73 | 553.78 | 100 | 39.24 | 171.7 | |
ROE | -1.92 | -0.77 | -2.62 | -3.65 | 3.82 | |
Capex per share | -0.19 | -0.06 | -0.01 | -0.01 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.59 | 0.1 | 0.04 | 0.05 | 0.01 | |
Net income per share | 0.34 | -1.04 | -0.85 | -0.59 | -0.11 | |
Operating cash flow per share | 0.61 | -0.42 | -0.86 | -0.79 | -0.15 | |
Free cash flow per share | 0.6 | -0.42 | -0.87 | -0.78 | -0.15 | |
Cash per share | 1.8 | 1.4 | 1.42 | 0.45 | 0.22 | |
Book value per share | -0.22 | -1.16 | -0.53 | -0.5 | 0.31 | |
Tangible book value per share | -1.75 | -2.69 | -1.76 | -1.53 | 0.01 | |
Share holders equity per share | -0.22 | -1.16 | -0.53 | -0.5 | 0.31 | |
Interest debt per share | 2.12 | 2.22 | 1.77 | 1.12 | -0.02 | |
Market cap | 7.5B | 11.39B | 4.92B | 1.19B | 1.36B | |
Enterprise value | 7.5B | 11.4B | 4.93B | 1.2B | 1.35B | |
P/E ratio | 587.46 | -290.31 | -123.65 | -36.32 | -64.94 | |
Price to sales ratio | 501.75 | 12.72K | 10.37K | 1.85K | 5.75K | |
POCF ratio | 1.31K | -2.89K | -489.81 | -107.96 | -198.66 | |
PFCF ratio | 1.32K | -2.85K | -482.23 | -109.53 | -198.66 | |
P/B Ratio | -3.7K | -1.04K | -785.63 | -170.82 | 92.41 | |
PTB ratio | -3.7K | -1.04K | -785.63 | -170.82 | 92.41 | |
EV to sales | 501.89 | 12.72K | 10.37K | 1.86K | 5.71K | |
Enterprise value over EBITDA | 1.83K | -1.29K | -558.7 | -168.62 | -359.57 | |
EV to operating cash flow | 1.31K | -2.89K | -490.12 | -108.72 | -197.25 | |
EV to free cash flow | 1.32K | -2.85K | -482.53 | -110.3 | -197.25 | |
Earnings yield | 0 | 0 | 0 | -0.01 | 0 | |
Free cash flow yield | 0 | 0 | 0 | -0.01 | -0.01 | |
Debt to equity | -9.4 | -1.83 | -3.15 | -2.1 | 0.04 | |
Debt to assets | 0.52 | 0.6 | 0.55 | 0.6 | 0.02 | |
Net debt to EBITDA | 0.52 | -0.77 | -0.35 | -1.17 | 2.57 | |
Current ratio | 1.07 | 0.74 | 0.83 | 0.33 | 2.11 | |
Interest coverage | 3.56 | -9.33 | -9.26 | -7.18 | 2.41 | |
Income quality | 1.79 | 0.4 | 1.01 | 1.35 | 1.31 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.22 | 3.29 | 5.67 | 3.76 | 10.52 | |
Research and developement to revenue | 0.47 | 6.89 | 12.65 | 7.24 | 5.29 | |
Intangibles to total assets | 0.39 | 0.43 | 0.4 | 0.59 | 0.49 | |
Capex to operating cash flow | -0.01 | 0.01 | 0.02 | -0.01 | 0 | |
Capex to revenue | 0 | -0.06 | -0.33 | 0.25 | 0 | |
Capex to depreciation | -1.15 | -1.6 | -4.79 | 3.85 | 0 | |
Stock based compensation to revenue | 0.05 | 0.94 | 1.8 | 1.39 | 4.04 | |
Graham number | 1.28 | 5.21 | 3.2 | 2.57 | 0.89 | |
ROIC | 0.18 | -0.93 | -0.63 | -0.87 | -0.24 | |
Return on tangible assets | 0.14 | -0.52 | -0.46 | -0.83 | -0.35 | |
Graham Net | -2.19 | -3.15 | -2.15 | -1.78 | -0.07 | |
Working capital | 1.3M | -5.7M | -3.99M | -14.94M | 6.65M | |
Tangible asset value | -16.44M | -25.32M | -20.68M | -21.38M | 286K | |
Net current asset value | -19.13M | -27.87M | -23.25M | -23.69M | -1.92M | |
Invested capital | -9.4 | -1.83 | -3.15 | -2.1 | 0.04 | |
Average receivables | 1.58M | 1.62M | 1.39M | 450.5K | 791K | |
Average payables | 1.81M | 2.16M | 4.22M | 3.16M | 770K | |
Average inventory | 22.5K | 21K | 19.5K | 18.5K | 9.5K | |
Days sales outstanding | 7.91 | 192.76 | 162.38 | 6.16 | 586.53 | |
Days payables outstanding | 246.65 | 418.35 | 908.98 | 95.47 | 287.49 | |
Days of inventory on hand | 3.75 | 2.9 | 3.1 | 2.29 | 0.36 | |
Receivables turnover | 11.38 | 0.47 | 0.55 | 14.61 | 0.15 | |
Payables turnover | 0.36 | 0.22 | 0.1 | 0.94 | 0.31 | |
Inventory turnover | 24 | 31 | 29 | 39.33 | 247 | |
ROE | -1.57 | 0.9 | 1.59 | 1.18 | -0.36 | |
Capex per share | 0 | -0.01 | -0.01 | 0.01 | 0 |
AVTX Frequently Asked Questions
What is Avalo Therapeutics, Inc. stock symbol ?
Avalo Therapeutics, Inc. is a US stock , located in Rockville of Md and trading under the symbol AVTX
What is Avalo Therapeutics, Inc. stock quote today ?
Avalo Therapeutics, Inc. stock price is $21.42 today.
Is Avalo Therapeutics, Inc. stock public?
Yes, Avalo Therapeutics, Inc. is a publicly traded company.